New Breakthrough in Anti-Cancer! Protein Degrader has Obtained Preclinical Proof of Concept for T-ALL Treatment
Acute lymphoblastic leukemia (ALL) is a common disease. B-ALL and T-ALL account for 85% and 15% of the two lymphatic lineages of ALL, respectively, but patients with T-ALL have poor life qualityRead More…